Moleculin Biotech Inc

-0.02 (-0.60%)
Regulatory, Other Pre-Announcement

Moleculin Receives Approval To Extend Dose Escalation In Phase 1/2 European Clinical Trial Evaluating Annamycin

Published: 07/13/2021 12:47 GMT
Moleculin Biotech Inc (MBRX) - Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia.
Moleculin Biotech Inc - Company Expects to Report Topline Results From Ongoing Phase 1/2 Study for Treatment of Aml in Second Half of 2022.
Moleculin Biotech Inc - Demonstrated Efficacy in 240 Mg/m² Cohort With Annamycin.
Moleculin Biotech Inc - Protocol Amendment Allows for Change in Dose Limiting Toxicity (dlt) Criteria for Future Enrolled Subjects.
Moleculin Biotech - Annamycin Demonstrated Little to No Cardiotoxicity, Avoids Multidrug Resistance, Has Been Shown to Be More Potent in Aml Cell Lines.